Ќ Ў®а ⥪бв®ў ⥬㠂’Ћ б ЇҐаҐў®¤®¬ (копия). Всемирная торговая организация
 Скачать 0.92 Mb.
|
Interested:in the distribution in the Sverdlovsk region of SKD-assembly of light commercial vehicles (LCV), as well as SKD or CKD-assembly of cars; in the distribution of manufacturing auto components in industrial sites of the Sverdlovsk region, as well as in the industrial special economic zone “Titanium Valley”.
Within the framework of the Development Strategy of the Sverdlovsk region until 2020, aimed at the increasing production of innovative products, is being formed the Chemical Technological Park “Tagil” (hereinafter – Technopark) on the production site of the largest Russian manufacturer of synthetic resins and plastics – “Uralkhimplast” (city of Nizhny Tagil). At the head of the group “Uralchimplast” is Austrian company “UCP Chemicals AG” – the main shareholder of the group (92%). Technopark’s area has nearby the rich mineral resource base, access to cheap oil and gas products. Industrial specialization of the Sverdlovsk region provides a stable and steady markets represented by the metallurgical, machine building, petrochemical, energy sectors and timber industry. Today the area has all necessary permits for the allocation of chemical plants, including dangerous, as well as network infrastructure facilities: boiler house, sewage disposal plant, landfill with the possibility of recycling, road and rail access routes, its own fleet of cars and rail cars, steam and gas-supplies, own accredited laboratory. The territory, unencumbered by buildings and structures, is 90 hectares and will be transferred for use by residents of the techno park. The Government of the Sverdlovsk region will provide support to potential residents of the industrial technology park with the state guarantees, tax concessions, simplifying the registration and licensing procedures for investors, etc. “Uralchimplast” guarantees assistance in the analysis of markets and products promotion, during registration REACH, sharing a distributive network, rail and motor car park, as well as all the infrastructure facilities in industrial technology park. From the municipal authorities of the city of Nizhny Tagil investors will be provided by measures of administrative support and tax benefits. Interested in placing productions of chemical concerns at the site of Technopark. Production of pharmaceuticals, medical equipment and medical supplies Taking into account the objectives of the Government of the Russian Federation to create a high-tech production of medicines, medical equipment and medical products in the Russian Federation, and the Concept of the Federal Target Program “Development of the Pharmaceutical and Medical Industry of the Russian Federation for the period up to 2020 and further prospects” (Government Decree of the Russian Federation of October 1, 2010 No. 1660-p), the Government of the Sverdlovsk region is developing the project of the Ural Pharmaceutical Cluster (hereinafter – Cluster). The strategic goal of creating the Cluster is forming in the region a high-tech complex of interrelated industries and infrastructure for the development, production and sale of modern medicines, medical equipment and medical products of high quality. In the Sverdlovsk region, historically established a complex conditions for the development of the pharmaceutical industry on a cluster basis, including the presence in the Middle Urals unique combination of cluster members, namely: 5 institutes of the Ural branch of the Russian Academy of Sciences and 6 industrial research institutes with qualified scientists and technologists who have the serious developments in the field of pharmacy; The Ural Federal University (51 thousand students) and the Ural State Medical Academy (10 thousand students) as base for research and training personnel for the pharmaceutical industry; Center for Military-Technical Problems of Biological Protection of Ministry of Defense (Yekaterinburg); 12 pharmaceutical companies in the region, including high-tech production of import pharmaceutical products by the standards of the European GMP, in particular, preparations of genetically engineered insulin human, infusion, peritoneal and others solutions, antiviral, anticancer nanomedicines, concentrates and automated water treatment apparatuses and hemodialysis systems, radiopharmaceuticals, etc.; significant public-private network of major consumers of the Cluster’s production – specialized dialysis centers, diabetes centers and clinics; strong links with foreign partners: research centers, manufacturers, service providers; the reliable production logistics system corresponding to international standards which development is provided through the construction of a regional pharmaceutical transportation and logistics hub in area 30 thousand sq. m. It should be noted that created within the Cluster OOO “Ural Center of biopharmaceutical technology” with the project “Development of innovator medicines to treat infections of viral etiology and diagnostic techniques of viral diseases” and OOO “Ural Nuclear Medicine Centre” with project “Targeting diagnostic and therapeutic multimodal agents on the support structure core-shell carbon” got the status of the residents of the Development Fund of the Centre for Development and Commercialization of New Technologies (the Skolkovo Innovation Fund). Along with the Skolkovo Innovation Fund the co-investor of the first project is a founder of the Ural Center of biopharmaceutical technology – Holding “Unona” (Yekaterinburg), and a co-investor of the Ural Nuclear Medical Center will be OOO “UralDial” (Yekaterinburg). The production volume of the finished pharmaceutical products in the Sverdlovsk region in 2010 became one of the largest in Russia and was about 3.0 billion rubles which in 3.1 times more than in 2005. Currently pharmaceutical enterprises of the region produce 55 titles which are included in the nationwide list of 652 vital and essential drugs, 23 items are at the registration and 332 in the advanced development. The further development of the Cluster will largely be based both on the existing and the newly created innovation infrastructure, including: Science park, uniting the scientific research and experimental laboratories and a vivarium for the development, preclinical and pilot testing of innovative products of the Cluster; Centers of high medical technologies (dialysis, diabetic, nuclear, etc.); companies – residents of the Skolkovo Innovation Fund in the Cluster, including the Urals Nuclear Medicine Center and the Ural Center of Biopharmaceutical Technology; Business incubator for the formation of the target groups of small innovative pharmaceutical companies and the personnel training center; joint scientific and innovative research products with foreign partners (e.g., Triazavirin – Dynamite Nobel, Germany; test strips for glucometers – Bayer, Germany; syringe insulin delivery system – Owen Mumford, UK; pacemakers – Medtronic, USA). According with the calculation of total annual output by the companies of the Cluster (medicines, medical equipment and expendable materials) made on the basis of the synergistic effect taken in the cooperation of the Cluster participants: by 2015 the volume of the production estimated in Euro 875 million and by 2020 – up to Euro 2,5 billion. Basing on the research results, which have defined the most socially-critical the Russian spheres of public health services, was compiled a list of more than 70 innovative, modern facilities, planned to create (or modernize) as part of the Ural pharmaceutical cluster for an overall amount of investment Euro 1 billion, the priority of which: the manufacture of infusion, peritoneal and other types of solutions, as well as their packaging; the manufacture of a substance and the finished pharma products of genetically engineered insulin human of trade mark Rosinsulin; the manufacture of dry and liquid dialysis concentrates, as well the artificial kidney apparatus, and the water treatment systems for dialysis department; the manufacture of isotopes of cesium-131 which are used in micro source radio radiation for the treatment of malignant tumors of the prostate gland (currently 100% exported to USA); the creation of the Ural Nuclear Medicine Center for diagnosis and therapy of malignant tumors using nuclear technology; the production of the substance and the finished pharmacy products of antiviral drugs, particularly of the innovative domestic drug of world level with a new molecule Triazavirin; the creation of a network of specialized dialysis centers for treatment patients with chronic renal failure through hemodialysis sessions. Since 2011, it is planned to create not highly specialized dialysis centers, but the comprehensive centers of advanced medical technologies, including the dialysis departments, diabetes treatment, brachytherapy, etc. About 200 centers are in the works to build across Russia; the first Russian production of glass package for the needs of pharmaceutical industry of the first hydrolytic class (ampoules, vials, cartridges). The key factors of the successful development of the Cluster are: a highly professional and experienced team of staff in all key direction of activity: more than 100 of them – the top managers of top-qualification, manufacturing staff are fully certified for compliance with EU GMP requirements, among the scientific staff – 3 academicians, 9 professors, 22 PhD. the presence of independent private funds which allow participating in the various government programs; the political support on the part of the Government at all levels; the private-public partnership: at the regional level it is implemented as part of the governor and special programs, agreements of intent with the co-financing from the regional budgets; at the federal level the enterprises of Cluster within the partnership with the state implement the pilot and the priority projects, including, jointly with the State corporations, funds and banks (Rosnauka, Skolkovo Innovation Fund, Vnesheconombank, Rosnano). In addition, under the “Strategy for Development of Pharmaceutical and Medical Industry of Russia till 2020” in the cluster is planned to implement 32 projects – among them upon 12 projects have already filed the applications in the similarly-named Federal Target Program. Among the priority ways of cooperation within a framework of the Ural pharmaceutical cluster the Government of the Sverdlovsk Region of the Russian Federation following are highlighted: joint experimentation in the sphere of modern, innovative medical products, medical equipment and active storages; international clinical trials of drugs for licensing receiving for its application at the partner countries; projects implementation of an allocation the joint manufactures of pharmaceuticals and medical equipment at the facilities of companies-participants of the cluster, including the production of hardware components and fully finished products, as well as the assembly of finished products from the supplied components; carrying out the joint scientific researches in the field of modern, innovative medicines, medical equipment and consumables; purchasing of the substances, strain-mfrs, substance and medicines manufacture patents. The Government of the Sverdlovsk region (Russia) will render to the partners of the Cluster all necessary assistance in selecting the sites for the plants, as well as provide the state support measures, tax privileges and preferences connected with the passing of the registration and licensing procedures. Monopolies Pure monopoly is a theoretical market structure where there is only one seller of a commodity or service, where entry into the industry is closed to potential competitors, and where the seller has complete control over the quan-, tity of goods offered for sale and the price at which goods are sold. Monopolies may begin by the granting of a patent or a copyright, by the possession of a superior skill or talent, or by the ownership of strategic capital. The huge capital investment necessary to organise a firm in some countries is a barrier to entry in these monopolistic fields and, thus, provides established corporations in these industries with potential monopoly power. At the same time, in recent years, many large U.S. corporations, viewed by many as the chief instrument of monopoly, have become vulnerable to new forms of competition. U.S. consumers can buy goods from foreign producers, pjthe case of automobile, they can purchase products made by Honda, Toyota, or Volvo, to name a few. The U.S. Government has tried to minimise the danger of monopolies through legislation. The euro crisisThe so bad, it's good theoryVETERAN market watchers will be familiar with those stages of the cycle when equities rally on bad news, on the grounds that the Federal Reserve would be prompted to cut interest rates. There seems to be a current attitude that only really, really bad news will force the European Central Bank and German government to do what is needed to rescue the euro. Here is David Owen of Jefferies. «It is important to recognise that the more contagion spreads to more countries inside EMU, the more likely the ECB is forced to pull the trigger and preannounce a transparent policy of buying Italian and Spanish bonds in size. This will particularly be the case if French spreads continue to widen relative to Germany, and the German sovereign has further problems issuing paper.» This seems a scenario fraught with danger. I am reminded of the great TV series "I, Claudius" in which Derek Jacobi, playing the stuttering emperor, allows his scheming wife Agrippina to promote her son Nero as his successor. Only by "letting the poison out" would the Romans realise how awful the imperial system was, Claudius reasoned, and that would provoke them to return to a republic. But Claudius is poisoned by his wife and the empire continues. We come back to the issue that there are short-term problems (debt financing) and long-term problems (uncompetitiveness) that afflict southern Europe and it is hard to come up with a plan that solves both issues. Quantitative easing deals with the first but does nothing for the latter; devaluation will solve the latter but might make the debt financing problem worse. Today's news is pretty dreadful. The Italians are having to pay 6.5% for six month debt (and two-year yields are 7.8%). Reuters has a story suggesting the Greeks are now suggesting creditors take a 75% haircut. That kind of demand will only make creditors more fearful of their potential losses on other European debt and make it even harder for governments to raise money. Is this really the end? |